Ruben Raychaudhuri

Oncology
825 Eastlake Ave E
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Deep learning-based histologic classifiers enable molecular subtyping of metastatic prostate cancer.

Deep learning-based histologic classifiers enable molecular subtyping of metastatic prostate cancer.

Journal: JCI insight
Published: August 06, 2026

PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.

PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.

Journal: Radiology
Published: March 31, 2026

Clinical Trial Protocol for LPS-Boost: Intensified [177Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.

Clinical Trial Protocol for LPS-Boost: Intensified [177Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 08, 2026

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.

Journal: Molecular cancer research : MCR
Published: January 14, 2026

Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer.

Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer.

Journal: JCO precision oncology
Published: December 05, 2025

Prognostic Value of Cycle 1 SPECT SUVmean in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617.

Prognostic Value of Cycle 1 SPECT SUVmean in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 30, 2025

Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer.

Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer.

Journal: JCO precision oncology
Published: September 19, 2025

Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer.

Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer.

Journal: The oncologist
Published: September 01, 2025

Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer.

Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer.

Journal: The oncologist
Published: September 01, 2025

Complexity of Prostate Cancer-Reply.

Complexity of Prostate Cancer-Reply.

Journal: JAMA
Published: July 09, 2025

Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617.

Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617.

Journal: The oncologist
Published: June 27, 2025

Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial.

Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial.

Journal: European urology
Published: April 23, 2025
Showing 1-12 of 27

Last Updated: 09/26/2026